Literature DB >> 9988226

BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.

T Uchida1, C Wang, T Sato, J Gao, R Takashima, A Irie, M Ohori, K Koshiba.   

Abstract

The tumor suppressor gene BRCA1 on chromosome 17q21 has been characterized and shown to be mutated in patients with familial breast and ovarian cancer. Several studies examined the relatives of women with breast cancer and noted an association with ovarian and prostate cancer. This study investigated 24 human prostate cancer specimens for BRCA1 gene mutations and loss of heterozygosity (LOH) on chromosome 17q21 assessed by the polymerase chain reaction. LOH was identified using 7 highly polymorphic tandem repeat markers on chromosome 17q21, in addition to an analysis of the whole coding region of the BRCA1 gene. Four of the 24 prostate cancer specimens showed LOH at one or more loci, all of which were histologically poorly differentiated (4 of 11) and stage D (4 of 15). One of the 24 cases showed a germ-line mutation of the BRCA1 gene, and a sister of this patient died of ovarian cancer. It appears that the BRCA1 gene is not frequently involved in the development of primary prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988226     DOI: 10.1002/(sici)1097-0215(19990219)84:1<19::aid-ijc4>3.0.co;2-s

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer.

Authors:  Si-Yi Hu; Tao Liu; Zhen-Zhen Liu; Elisa Ledet; Cruz Velasco-Gonzalez; Diptasri M Mandal; Shahriar Koochekpour
Journal:  Asian J Androl       Date:  2010-02-22       Impact factor: 3.285

2.  BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood.

Authors:  Natalia Bednarz; Elke Eltze; Axel Semjonow; Michael Rink; Antje Andreas; Lennart Mulder; Juliane Hannemann; Margit Fisch; Klaus Pantel; Heinz-Ulrich G Weier; Krzysztof P Bielawski; Burkhard Brandt
Journal:  Clin Cancer Res       Date:  2010-06-30       Impact factor: 12.531

Review 3.  Androgen receptor signaling and mutations in prostate cancer.

Authors:  Shahriar Koochekpour
Journal:  Asian J Androl       Date:  2010-08-16       Impact factor: 3.285

4.  Detection of hypermethylation BRCA1/2 gene promoter in breast tumours among Moroccan women.

Authors:  Imane Saif; Amal Bouziyane; Mustapha Benhessou; Mohamed El Karroumi; Moulay Mustapha Ennaji
Journal:  Mol Biol Rep       Date:  2021-09-30       Impact factor: 2.316

5.  Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.

Authors:  Hagit Schayek; Kathy Haugk; Shihua Sun; Lawrence D True; Stephen R Plymate; Haim Werner
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

6.  Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer.

Authors:  A Fosså; R Siebert; H C Aasheim; G M Maelandsmo; A Berner; S D Fosså; E Paus; E B Smeland; G Gaudernack
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

7.  Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer.

Authors:  Maria Nowacka-Zawisza; Ewa Forma; Maciej Walczak; Waldemar Różański; Magdalena Bryś; Wanda M Krajewska
Journal:  Med Oncol       Date:  2015-10-03       Impact factor: 3.064

8.  A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.

Authors:  Shona H Lang; Stephanie L Swift; Heath White; Kate Misso; Jos Kleijnen; Ruben G W Quek
Journal:  Int J Oncol       Date:  2019-07-16       Impact factor: 5.650

9.  Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.

Authors:  Edward J Saunders; Tokhir Dadaev; Daniel A Leongamornlert; Sarah Jugurnauth-Little; Malgorzata Tymrakiewicz; Fredrik Wiklund; Ali Amin Al Olama; Sara Benlloch; David E Neal; Freddie C Hamdy; Jenny L Donovan; Graham G Giles; Gianluca Severi; Henrik Gronberg; Markus Aly; Christopher A Haiman; Fredrick Schumacher; Brian E Henderson; Sara Lindstrom; Peter Kraft; David J Hunter; Susan Gapstur; Stephen Chanock; Sonja I Berndt; Demetrius Albanes; Gerald Andriole; Johanna Schleutker; Maren Weischer; Børge G Nordestgaard; Federico Canzian; Daniele Campa; Elio Riboli; Tim J Key; Ruth C Travis; Sue A Ingles; Esther M John; Richard B Hayes; Paul Pharoah; Kay-Tee Khaw; Janet L Stanford; Elaine A Ostrander; Lisa B Signorello; Stephen N Thibodeau; Daniel Schaid; Christiane Maier; Adam S Kibel; Cezary Cybulski; Lisa Cannon-Albright; Hermann Brenner; Jong Y Park; Radka Kaneva; Jyotsna Batra; Judith A Clements; Manuel R Teixeira; Jianfeng Xu; Christos Mikropoulos; Chee Goh; Koveela Govindasami; Michelle Guy; Rosemary A Wilkinson; Emma J Sawyer; Angela Morgan; Douglas F Easton; Ken Muir; Rosalind A Eeles; Zsofia Kote-Jarai
Journal:  PLoS Genet       Date:  2014-02-13       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.